Clinical characteristics of interim-PET negative patients with a positive end PET from the prospective HD08-01 FIL study.
Adult
Antineoplastic Combined Chemotherapy Protocols
/ administration & dosage
Autografts
Bleomycin
/ administration & dosage
Dacarbazine
/ administration & dosage
Disease-Free Survival
Doxorubicin
/ administration & dosage
Female
Fluorodeoxyglucose F18
/ administration & dosage
Hodgkin Disease
/ diagnostic imaging
Humans
Male
Positron-Emission Tomography
Prospective Studies
Stem Cell Transplantation
Survival Rate
Vinblastine
/ administration & dosage
Advanced Hodgkin lymphoma
Interim-PET
Prognosis
Journal
Annals of hematology
ISSN: 1432-0584
Titre abrégé: Ann Hematol
Pays: Germany
ID NLM: 9107334
Informations de publication
Date de publication:
Feb 2020
Feb 2020
Historique:
received:
15
04
2019
accepted:
06
12
2019
pubmed:
25
12
2019
medline:
30
1
2020
entrez:
25
12
2019
Statut:
ppublish
Résumé
FDG-positron emission tomography (PET) performed early during therapy in advanced Hodgkin lymphoma patients has been confirmed as being important for progression-free survival. A group of patients with a negative interim-PET (i-PET) showed a positive end induction PET (e-PET). The aim of this study was to evaluate the clinical characteristics of patients with a positive e-PET as a secondary end point of the HD0801 study. A total of 519 patients with advanced-stage de novo Hodgkin lymphoma received initial treatment and underwent an i-PET. Patients with negative results continued the standard treatment. i-PET negative patients were then evaluated for response with an e-PET and those patients found to have a positive one were also then given a salvage therapy. Among 409 i-PET negative, 16 interrupted the therapy, 393 patients were evaluated with an e-PET, and 39 were positive. Sixteen out of 39 underwent a diagnostic biopsy and 15 were confirmed as HD. Seventeen out of 39 e-PET were reviewed according to the Deauville Score and, in sixteen, it was confirmed positive (10 DS 5, 6 DS 4). With the exception of high LDH value at diagnosis (p = 0.01; HR 95% CI 1.18-4.89), no clinical characteristics were significantly different in comparison with e-PET negative patients. Positive e-PET after a negative i-PET has a worse outcome when compared with i-PET positive patients salvaged with therapy intensification. It was not possible to identify clinical characteristics associated with a positive e-PET.
Identifiants
pubmed: 31872361
doi: 10.1007/s00277-019-03889-3
pii: 10.1007/s00277-019-03889-3
doi:
Substances chimiques
Fluorodeoxyglucose F18
0Z5B2CJX4D
Bleomycin
11056-06-7
Vinblastine
5V9KLZ54CY
Dacarbazine
7GR28W0FJI
Doxorubicin
80168379AG
Types de publication
Clinical Trial
Comparative Study
Journal Article
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
283-291Références
Hasenclever D, Diehl V (1998) A prognostic score for advanced Hodgkin’s disease: International Prognostic Factors Project on advanced Hodgkin’s disease. N Engl J Med 339:1506–1514
doi: 10.1056/NEJM199811193392104
Terasawa T, Lau J, Bardet S et al (2009) Fluorine-18-fluorodeoxyglucose positron emission tomography for interim response assessment of advanced-stage Hodgkin’s lymphoma and diffuse large B-cell lymphoma: A systemic review. J Clin Oncol 27:1906–1914
doi: 10.1200/JCO.2008.16.0861
Hutchings M, Loft A, Hansen M et al (2006) FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma. Blood 107:52–59
doi: 10.1182/blood-2005-06-2252
Gallamini A, Rigacci L, Merli F et al (2006) The predictive value of positron emission tomography scanning performed after two courses of standard therapy on treatment outcome in advanced stage Hodgkin’s disease. Haematologica 91:475–481
pubmed: 16585014
Zinzani PL, Tani M, Fanti S et al (2006) Early positron emission tomography (PET) restaging: a predictive final response in Hodgkin’s disease patients. Ann Oncol 17:1296–1300
doi: 10.1093/annonc/mdl122
Gallamini A, Hutchings M, Rigacci L et al (2007) Early interim 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin’s lymphoma: a report from a joint Italian-Danish study. J Clin Oncol 25:3746–3752
doi: 10.1200/JCO.2007.11.6525
Zinzani PL, Rigacci L, Stefoni V et al (2012) Early interim 18F-FDG PET in Hodgkin’s lymphoma: evaluation on 304 patients. Eur J Nucl Med Mol Imaging 39:4–12
doi: 10.1007/s00259-011-1916-8
Viviani S, Zinzani PL, Rambaldi A et al (2011) ABVD versus BEACOPP for Hodgkin’s lymphoma when high-dose salvage is planned. N Engl J Med 365:203–212
doi: 10.1056/NEJMoa1100340
Mounier N, Brice P, Bologna S et al (2014) ABVD (8 cycles) versus BEACOPP (4 escalated cycles > 4 baseline): final results in stage III-IV low-risk Hodgkin lymphoma (IPS 0-2) of the LYSA H34 randomized trial. Ann Oncol 25:1622–1628
doi: 10.1093/annonc/mdu189
Eichenauer DA, Becker I, Monsef I et al (2017) Secondary malignant neoplasms, progression-free survival and overall survival in patients treated for Hodgkin lymphoma: a systematic review and meta-analysis of randomized clinical trials. Haematologica 102(10):1748–1757. https://doi.org/10.3324/haematol.2017.167478
doi: 10.3324/haematol.2017.167478
pubmed: 28912173
pmcid: 5622859
Behringer K, Mueller H, Goergen H et al (2013) (2012) Gonadal function and fertility in survivors after Hodgkin lymphoma treatment within the German Hodgkin Study Group HD13 to HD15 trials. J Clin Oncol 31(2):231–239. https://doi.org/10.1200/JCO.2012.44.3721
doi: 10.1200/JCO.2012.44.3721
pubmed: 23150709
Borchmann P, Goergen H, Kobe C et al (2018) PET-guided treatment in patients with advanced-stage Hodgkin’s lymphoma (HD18): final results of an open-label, international, randomised phase 3 trial by the German Hodgkin Study Group. Lancet 390(10114):2790–2802. https://doi.org/10.1016/S0140-6736(17)32134-7
doi: 10.1016/S0140-6736(17)32134-7
pubmed: 29061295
Gallamini A, Patti C, Viviani S et al (2011) Early chemotherapy intensification with BEACOPP in advanced-stage Hodgkin lymphoma patients with a interim-PET positive after two ABVD courses. Br J Haematol 152:551–560
doi: 10.1111/j.1365-2141.2010.08485.x
Dann EJ, Blumenfeld Z, Bar-Shalom R et al (2012) A 10-year experience with treatment of high and standard risk Hodgkin disease: six cycles of tailored BEACOPP, with interim scintigraphy, are effective and female fertility is preserved. Am J Hematol 87:32–36
doi: 10.1002/ajh.22187
Radford J, Illidge T, Counsell N et al (2015) Results of a trial of PET-directed therapy for early-stage Hodgkin’s lymphoma. N Engl J Med 372(17):1598–1607
doi: 10.1056/NEJMoa1408648
André MPE, Girinsky T, Federico M et al (2017) Early positron emission tomography response-adapted treatment in stage I and II HodgkinLymphoma: final results of the randomized EORTC/LYSA/FIL H10 trial. J Clin Oncol 35(16):1786–1794
doi: 10.1200/JCO.2016.68.6394
Borchmann P, Haverkamp H, Lohri A et al (2017) Progression-free survival of early interim PET-positive patients with advanced stage Hodgkin’s lymphoma treated with BEACOPPescalated alone or in combination with rituximab (HD18): an open-label, international, randomised phase 3 study by the German Hodgkin Study Group. Lancet Oncol 18(4):454–463
doi: 10.1016/S1470-2045(17)30103-1
Gallamini A, Tarella C, Viviani S et al (2018) Early chemotherapy intensification with escalated BEACOPP in patients with advanced-stage Hodgkin lymphoma with a positive interim positron emission tomography/computed tomography scan after two ABVD cycles: long-term results of the GITIL/FIL HD 0607 trial. J Clin Oncol 36(5):454–462
doi: 10.1200/JCO.2017.75.2543
Zinzani PL, Broccoli A, Gioia DM et al (2016) Interim positron emission tomography response-adapted therapy in advanced-stage Hodgkin lymphoma: final results of the phase II part of the HD0801 study. J Clin Oncol 34(12):1376–1385
doi: 10.1200/JCO.2015.63.0699
Johnson P, Federico M, Kirkwood A et al (2016) Adapted treatment guided by interim PET-CT scan in advanced Hodgkin’s lymphoma. N Engl J Med 374(25):2419–2429
doi: 10.1056/NEJMoa1510093
Press OW, Li H, Schoder H et al (2016) US Intergroup trial of response-adapted therapy for stage III to IV Hodgkin lymphoma using early interim fluorodeoxyglucose-positron emission tomognraphy imaging: Southwest Oncology Group S0816. J Clin Oncol 34(17):2020–2027
doi: 10.1200/JCO.2015.63.1119
Juweid ME, Stroobants S, Hoekstra OS et al (2007) Imaging Subcommittee of International Harmonization Project in Lymphoma. Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma. J Clin Oncol 25(5):571–578
doi: 10.1200/JCO.2006.08.2305
Gallamini A, Barrington SF, Biggi A et al (2014) The predictive role of interim positron emission tomography for Hodgkin lymphoma treatment outcome is confirmed using the interpretation criteria of the Deauville five-point scale. Haematologica 99(6):1107–1113
doi: 10.3324/haematol.2013.103218
Skoetz N, Trelle S, Rancea M et al (2013) Effect of initial treatment strategy on survival of patients with advanced-stage Hodgkin’s lymphoma: a systematic review and network meta-analysis. Lancet Oncol 14:943–952
doi: 10.1016/S1470-2045(13)70341-3
Mesguich C, Cazeau AL, Bouabdallah K et al (2016) Hodgkin lymphoma: a negative interim-PET cannot circumvent the need for end-of-treatment-PET evaluation. Br J Haematol 175(4):652–660
doi: 10.1111/bjh.14292
Kobe C, Dietlein M, Franklin J et al (2008) Positron emission tomography has a high negative predictive value for progression or early relapse for patients with residual disease after first-line chemotherapy in advanced-stage Hodgkin lymphoma. Blood 112(10):3989–3994
doi: 10.1182/blood-2008-06-155820
Barnes JA, LaCasce AS, Zukotynski K et al (2011) End-of-treatment but not interim PET scan predicts outcome in nonbulky limited-stage Hodgkin’s lymphoma. Ann Oncol 22(4):910–915
doi: 10.1093/annonc/mdq549
Cheson BD (2007) The International Harmonization Project for response criteria in lymphoma clinical trials. Hematol Oncol Clin North Am Rev 21(5):841–854
doi: 10.1016/j.hoc.2007.06.011
Barrington SF, Kirkwood AA, Franceschetto A et al (2016) PET-CT for staging and early response: results from the response-adapted therapy in advanced Hodgkin lymphoma study. Blood 127(12):1531–1538
doi: 10.1182/blood-2015-11-679407
Armand P, Engert A, Younes A et al (2018) Nivolumab for relapsed/refractory classic Hodgkin lymphoma after failure of autologous hematopoietic cell transplantation: extended follow-up of the multicohort single-arm phase II CheckMate 205 trial. J Clin Oncol 36(14):1428–1439
doi: 10.1200/JCO.2017.76.0793